Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies

• Type: Another Publication in an International Scientific Journal
• Date: 2015

Authors

Costa Monteiro, IDC (Author) Other; Madureira, P (Author) Other; de Vasconscelos, A (Author) Other; Daniel Pozza (Author) FMUP; de Mello, RA (Author) Other

Journal

Title: Pharmacogenomics

Vol. 16

Pages: 257-271

ISSN: 1462-2416

Publisher: ASHLEY PUBLICATIONS LTD

Indexing

ISI Web of Knowledge - 22 Citations

Scopus - 20 Citations

Other information

Authenticus ID: P-00A-7CM

DOI: 10.2217/pgs.14.133

Abstract (EN): HER2-targeted therapies have radically changed the prognosis of HER2-positive breast cancer over the last few years. However, resistance to these therapies has been a constant, leading to treatment-failure and new tumor progression. Recently, the kinase-impaired HER3 emerged as a pivotal player in oncogenic signaling, with an important role in both non-treated progression and treatment response. HER2/HER3 dimerization is required for full signaling potential and constitutes the key oncogenic unit. Also, when inhibiting PI3K/AKT pathway (as with anti-HER2 drugs) feedback mechanisms lead to a rebound in HER3 activity, which is one of the main roads to resistance. As current strategies to treat HER2-positive breast cancer are unable to inhibit this feedback response, two great promises emerged: the combination of targeted-therapies and drugs targeting HER3. In this article HER2 and HER3-targeted drugs and possible combinations between them, as well as the biomarkers to predict and monitor these drugs effect, are reviewed.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 15